Literature DB >> 18397975

The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency.

Larissa G Gomes1, Ningwu Huang, Vishal Agrawal, Berenice B Mendonça, Tania A S S Bachega, Walter L Miller.   

Abstract

CONTEXT: 21-hydroxylase deficiency (21OHD) is a common genetic disorder caused by mutations in the CYP21A2 gene, which encodes the adrenal 21-hydroxylase, microsomal P450c21. CYP21A2 gene mutations generally correlate well with impaired P450c21 enzymatic activity and the clinical findings in 21OHD, but occasional discrepancies between genotype and phenotype suggest the effects of modifier genes. Mutations in P450 oxidoreductase (POR), the protein that transfers electrons from reduced nicotinamide adenine dinucleotide phosphate to all microsomal P450s, can ameliorate the 21OHD phenotype and, therefore, could be a modifier gene.
OBJECTIVES: We sought to identify POR variants in patients with 21OHD having discordant phenotype and genotype, and to evaluate their effect on 21-hydroxylase activity. PATIENTS AND METHODS: We determined the CYP21A2 genotypes of 313 Brazilian patients with 21OHD and correlated the genotype and phenotype. The POR gene was sequenced in 17 patients with discordant genotype and phenotype. Wild-type and A503V POR, and P450c21 were expressed in bacteria and reconstituted in vitro. Activities were assayed by conversion of [(14)C]progesterone to deoxycorticosterone and [(3)H]17-hydroxyprogesterone to 11-deoxycortisol, and assessed by thin layer chromatography and phosphorimaging.
RESULTS: The A503V POR variant was found in 10 of 30 alleles, the same ratio as in the normal population. There were no significant differences in Michaelis constant, maximum velocity and maximum velocity/Michaelis constant of 21-hydroxylase activity supported by wild-type and A503V POR.
CONCLUSION: The only POR missense polymorphism found in atypical 21OHD patients was A503V. Although A503V reduces P450c17 enzymatic activity, it does not influence P450c21 activity, indicating that POR A503V does not modify the 21OHD phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397975      PMCID: PMC2453048          DOI: 10.1210/jc.2008-0304

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Congenital adrenal hyperplasia.

Authors:  Phyllis W Speiser; Perrin C White
Journal:  N Engl J Med       Date:  2003-08-21       Impact factor: 91.245

2.  Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population.

Authors:  J Jääskeläinen; A Levo; R Voutilainen; J Partanen
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

3.  Congenital adrenal hyperplasia (21-hydroxylase deficiency) without demonstrable genetic mutations.

Authors:  S Nimkarn; B I Cerame; J Q Wei; M Dumic; R Zunec; L Brkljacic; V Skrabić; M I New; R C Wilson
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

4.  Molecular genotyping in Brazilian patients with the classical and nonclassical forms of 21-hydroxylase deficiency.

Authors:  T A Bachega; A E Billerbeck; G Madureira; J A Marcondes; C A Longui; M V Leite; I J Arnhold; B B Mendonca
Journal:  J Clin Endocrinol Metab       Date:  1998-12       Impact factor: 5.958

Review 5.  The molecular genetics of 21-hydroxylase deficiency.

Authors:  W L Miller; Y Morel
Journal:  Annu Rev Genet       Date:  1989       Impact factor: 16.830

6.  Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.

Authors:  Ningwu Huang; Amit V Pandey; Vishal Agrawal; William Reardon; Pablo D Lapunzina; David Mowat; Ethylin Wang Jabs; Guy Van Vliet; Joseph Sack; Christa E Flück; Walter L Miller
Journal:  Am J Hum Genet       Date:  2005-03-25       Impact factor: 11.025

7.  Low frequency of CYP2B deletions in Brazilian patients with congenital adrenal hyperplasia due to 21-hydroxylas deficiency.

Authors:  T A Bachega; A E Billerbeck; G Madureira; I J Arnhold; M A Medeiros; J A Marcondes; C A Longui; W Nicolau; W Bloise; B B Mendonca
Journal:  Hum Hered       Date:  1999-01       Impact factor: 0.444

8.  Variable ACTH-stimulated 17-hydroxyprogesterone values in 21-hydroxylase deficiency carriers are not related to the different CYP21 gene mutations.

Authors:  Tânia A S S Bachega; Enecy M L Brenlha; Ana E C Billerbeck; José A M Marcondes; Guiomar Madureira; Ivo J P Arnhold; Berenice B Mendonca
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

9.  Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome.

Authors:  Christa E Flück; Toshihro Tajima; Amit V Pandey; Wiebke Arlt; Kouji Okuhara; Charles F Verge; Ethylin Wang Jabs; Berenice B Mendonça; Kenji Fujieda; Walter L Miller
Journal:  Nat Genet       Date:  2004-02-01       Impact factor: 38.330

10.  Steroid 21-hydroxylase deficiency: genotype may not predict phenotype.

Authors:  R C Wilson; A B Mercado; K C Cheng; M I New
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

View more
  16 in total

1.  Consequences of POR mutations and polymorphisms.

Authors:  Walter L Miller; Vishal Agrawal; Duanpen Sandee; Meng Kian Tee; Ningwu Huang; Ji Ha Choi; Kari Morrissey; Kathleen M Giacomini
Journal:  Mol Cell Endocrinol       Date:  2010-11-09       Impact factor: 4.102

2.  Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.

Authors:  Xiuling Zhang; Lei Li; Xinxin Ding; Laurence S Kaminsky
Journal:  Drug Metab Dispos       Date:  2011-05-11       Impact factor: 3.922

Review 3.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

4.  Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese.

Authors:  Wu-Tao Zeng; Qing Xu; Cheng-Hsun Li; Wei-Yan Chen; Xiu-Ting Sun; Xiang Wang; Yi-Ying Yang; Hui Shi; Zhi-Sheng Yang
Journal:  Eur J Clin Pharmacol       Date:  2016-08-04       Impact factor: 2.953

Review 5.  Pharmacogenetics in Jewish populations.

Authors:  Yao Yang; Inga Peter; Stuart A Scott
Journal:  Drug Metabol Drug Interact       Date:  2014

6.  Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations.

Authors:  Mária Tomková; Christopher C Marohnic; David Gurwitz; Ondřej Seda; Bettie Sue Siler Masters; Pavel Martásek
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

7.  Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.

Authors:  Vishal Agrawal; Ji Ha Choi; Kathleen M Giacomini; Walter L Miller
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

8.  Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.

Authors:  Duanpen Sandee; Kari Morrissey; Vishal Agrawal; Harrison K Tam; Melissa A Kramer; Timothy S Tracy; Kathleen M Giacomini; Walter L Miller
Journal:  Pharmacogenet Genomics       Date:  2010-11       Impact factor: 2.089

9.  Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.

Authors:  Larissa G Gomes; Ningwu Huang; Vishal Agrawal; Berenice B Mendonça; Tania A S S Bachega; Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

Review 10.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.